Eunhye Jo

Molecular Size as a Constraint Rather Than a Design Principle: A Scoping Review of Departures from the Antibody/Small-Molecule Reference Model among FDA-Approved Oncology Antibody-Class Agents and Small-Molecule Protein Kinase Inhibitors

Background. In 2006, Imai and Takaoka set out a reference model contrasting monoclonal antibodies (mAbs) with small-molecule inhibitors, stating that mAbs “can only act on molecules that are expressed on the cell surface or secreted” whereas small molecules “can therefore be deve...